Eli Lilly Posted $23B in Revenue. So Why Did the Stock Fall? The Answer Is $3.03.
Eli Lilly (NYSE: LLY) delivered Q2 2026 revenue of $22,974M — a 48% year-over-year increase — while non-GAAP EPS rose 33% to $8.38 and the company raised its full-year revenue guidance to $85.0B–$87.0B, results that by any conventional measure should have sent shares higher. Instead, LLY fell on the day of the announcement, and the explanation lives inside a single accounting line: $3.03 per share in acquired in-process research and development (IPR&D) expenses, representing $2.8B charged from the acquisitions of Orna Therapeutics, Ajax Therapeutics, Kelonia, and Centessa. This charge more than offset management's $2.78 midpoint raise to underlying non-GAAP EPS guidance, producing a paradox where the fundamental business outlook improved yet the final 2026 EPS guidance range settled lower at $35.50–$36.50. Global volumes surged 60% but net realized prices fell 13% globally, with international markets absorbing a 36% price collapse driven primarily by Mounjaro's entry into China's National Reimbursement Drug List — a mechanism distinct from a traditional price war and potentially exportable to other large markets. The Mounjaro-Zepbound duo generated roughly $14.87B in combined quarterly revenue — approximately 65% of total sales — creating a concentration risk that compounds the pricing concern. Novo Nordisk shares also fell roughly 5% on the same day the Danish drugmaker reported near-stagnant full-year guidance of 0% to minus 6%, suggesting the market is repricing the GLP-1 category as a whole rather than any single company's quarter. Retatrutide's planned Q1 2027 BLA submission across three indications and the additional $4.5B Indiana manufacturing commitment are the pivotal variables that will ultimately determine whether Lilly's aggressive invest-while-growing model justifies the premium it commands.